Institut Gustave Roussy

Villejuif, Val-de-marne 94805

6 studies enrolling now · 22 studies all time

What they study most

Acute Myeloid Leukemia (AML), Advanced Malignant Neoplasm, Advanced Nonhematologic Malignancies, Advanced Solid Tumor, Advanced or Metastatic Gastric or Gastroesophageal Cancer, Advanced or Metastatic Solid Tumor, Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC), Brain Metastases, Breast Cancer, CLL/SLL, Cancer of the Prostate, Carcinoma, Merkel Cell

Studies at this site

• The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) — Recruiting now
• Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC) — Recruiting now
• Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer — Recruiting now
• Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML — Recruiting now
• Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer — Recruiting now
• A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence — Recruiting now
• Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06) — Running, not enrolling
• A Study of TAS3351 in NSCLC Patients With EGFRmt — Stopped early
• TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations — Running, not enrolling
• DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02] — Completed
• Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma — Completed
• Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer — Completed
• A Study of NB003 in Patients With Advanced Malignancies — Completed
• DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03] — Running, not enrolling
• Futibatinib in Patients With Specific FGFR Aberrations — Stopped early
• Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04] — Running, not enrolling
• A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma — Completed
• Avelumab in Participants With Merkel Cell Carcinoma (JAVELIN Merkel 200) — Completed
• A Study of H3B-8800 (RVT-2001) in Participants With Lower Risk Myelodysplastic Syndromes — Stopped early
• HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL — Withdrawn before enrolling
• A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies — Completed
• An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma. — Completed